Beta Bionics

Pharmacy Channel Adoption And Bihormonal Pipeline Will Drive Long Term Diabetes Care Impact

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

14 Dec 25

Views

14 Dec

US$16.82

AnalystConsensusTarget's Fair Value

US$31.30

46.3% undervalued

11.6%

21.2%

11.6%

21.2%

Author's Valuation

US$31.346.3% undervalued

AnalystConsensusTarget Fair Value

Valuator

Company Info

Notes

AnalystConsensusTarget Fair Value

US$31.3

46.3% undervalued

Future estimation in

Revenue

Profit Margin

Future PE

Est. Revenue

Forecast revenue growth rate

25.78%

Historical revenue growth rate

N/A

Medical Equipment revenue growth rate

0.44%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.45%

Calculation

US$30.32m

Earnings '28

59.43x

PE Ratio '28

US$1.80b

Market Cap '28

US$1.80b

Market Cap '28

46.12m

No. shares '28

US$39.07

Share Price '28

US$39.07 Share Price '28

Discounted to 2025 @ 7.67% p.a.

US$31.30

Fair Value '25